52
Participants
Start Date
January 24, 2024
Primary Completion Date
April 23, 2024
Study Completion Date
April 23, 2024
ACC017 tablets
ACC017 tablets 5 mg, 20 mg, 40 mg, 80 mg, 120 mg, and 160 mg (tentative) with matching placebo
Emtricitabine and Tenofovir Alafenamide Fumarate Tablets
Participants received a single oral dose of ACC017 tablets with emtricitabine and tenofovir alafenamide fumarate tablets under the fasting condition.
RECRUITING
Beijing Ditan Hospital Capital Medical University, Beijing
Lead Sponsor
Collaborators (1)
Chengdu Aidea Pharmaceutical Technology Co., Ltd
INDUSTRY
Jiangsu Aidea Pharmaceutical Co., Ltd
INDUSTRY